

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA shall not be responsible for any consequences resulting from the use of this English version.

Revision of PRECAUTIONS

Colistin sodium methanesulfonate (injections)

May 8, 2024

Therapeutic category

Antibiotic preparations acting mainly on gram-negative bacteria

Non-proprietary name

Colistin sodium methanesulfonate (injections)

Safety measure

PRECAUTIONS should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revised language is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS (N/A)	8. IMPORTANT PRECAUTIONS <u>Hypokalaemia, hypomagnesaemia, and hypocalcaemia may occur.</u> <u>Periodic tests should be performed.</u>
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Hypokalaemia, hypomagnesaemia, hypocalcaemia, metabolic alkalosis</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp